Delays As Korea Grapples With Immuno-Oncology Drug Coverage
This article was originally published in PharmAsia News
Executive Summary
With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.